About this trial
This study is being done to better understand whether meal replacements can be an effective tool for weight loss and treatment of elevated blood sugars in people with obesity/overweight and diabetes/pre-diabetes who have a low income.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18-65
Body mass index (BMI) greater than or equal to 27 kg/m²
HgA1C greater than or equal to 5.7 percent or fasting glucose greater than or equal to 100mg/dL within the previous 6 months
Low-income as defined by having a family income at or below 400 percent of the federal poverty level guidelines for 2022
Disqualifiers
Current use of antihyperglycemic agents (other than metformin) or approved anti- obesity medications or plans to start such regimens over the 3 months post-study enrollment
HbA1c greater than or equal to 10 percent
Plans to pursue bariatric surgery over the 6 months post-study enrollment
Weight loss of greater than 5 kg within the previous 3 months
Trial population
Adults with overweight or obesity and pre-diabetes or diabetes and low income
Trial design
Case-only
Prospective
Treatments tested in this trial
Bariatrix Meal Replacement Products
Dietary supplementMeal replacement products offered through the Massachusetts General Hospital Weight Center.
Treatment groups
Trial outcomes
Primary outcomes
Body weight reduction
Reduction in body weight by greater than or equal to 5 percent
Hemoglobin A1c reduction
Reduction of Hemoglobin A1c by greater than or equal to 0.5 percent
Secondary outcomes
Program adherence
Adherence with the program, and potential reasons for non-adherence as assessed with bi-weekly questionnaires
Sponsors and contacts
Click on the lead sponsor to view all of their trials.